Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage
نویسندگان
چکیده
Aaron Kesselheim and colleagues examine orphan-designated drugs approved between 2009 and 2015 in the United States.
منابع مشابه
State of the art of rare disease activities around the world: overview of the non-European landscape
With support from patient associations, political frameworks for rare diseases have been established throughout the world albeit with varying definitions for rare diseases. In the USA, the National Organization for Rare Disorders was instrumental in passing the 1983 Orphan Drug Act and the 2002 Rare Disease Act, which includes medical devices and dietary products as orphan products. In 2011, th...
متن کاملAre payers treating orphan drugs differently?
BACKGROUND Some orphan drugs can cost hundreds of thousands of dollars annually per patient. As a result, payer sensitivity to the cost of orphan drugs is rising, particularly in light of increased numbers of new launches in recent years. In this article, we examine payer coverage in the United States, England and Wales, and the Netherlands of outpatient orphan drugs approved between 1983 and 2...
متن کاملOrphan drug incentives in the pharmacogenomic context: policy responses in the US and Canada
Advances in pharmacogenomic research and increasing industry interest in personalized medicine have important implications for the way that orphan drug policies are interpreted and applied. Concerns have been raised about the potential impact of pharmacogenomics and new genomic technologies on our understanding of how disease categories are delineated, and subsequently, how the concept of rare ...
متن کاملA discrete choice experiment investigating preferences for funding drugs used to treat orphan diseases: an exploratory study.
Policy debate about funding criteria for drugs used to treat rare, orphan diseases is gaining prominence. This study presents evidence from a discrete choice experiment using a convenience sample of university students to investigate individual preferences regarding public funding for drugs used to treat rare diseases and common diseases. This pilot study finds that: other things equal, the res...
متن کاملInsurance companies' perspectives on the orphan drug pipeline.
BACKGROUND Rare diseases are of increasing concern to private and public healthcare insurance plans. Largely neglected by manufacturers before the 1983 passing of the Orphan Drug Act (ODA), orphan drugs have become a commercialization target of steadily increasing importance to the healthcare industry. The ODA mandates the coverage of rare diseases, which are defined in research communities as ...
متن کامل